Evofem Biosciences (EVFM) Misses Q3 EPS by 34c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. LYB
2. REGN
3. LITE
4. CL
5. BP
6. RELIANCE:I
7. NVT
8. OKTA
9. ABBV
10. CVX

Go back to Evofem Biosciences (EVFM) Misses Q3 EPS by 34c

Evofem Biosciences (EVFM) Reports Complete Phase 3 Clinical Trial of Amphora for Prevention of Pregnancy

November 8, 2018 6:51 AM EST

Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced the last patient has completed her last visit in AMPOWER, the second Phase 3 clinical trial of Amphora® (L-lactic acid, citric acid and potassium bitartrate), its lead Multipurpose Vaginal pH Regulator (MVP-R) product candidate, for the prevention of pregnancy.

Amphora is an investigational, first-in-class MVP-R designed to give a woman control over some of the most intimate issues of her life and health. This non-hormonal, non-systemic vaginal gel is being developed for woman-controlled birth control as well as prevention of certain sexually transmitted infections... More